anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Echocardiographic guidance in left atrial appendage (LAA) closure procedures is increasingly recognized for its potential to enhance patient outcomes in atrial fibrillation (AF). This retrospective study assesses its impact on hospital stay duration, readmission rates and surgical site wound complications in 200 AF patients. Divided equally into an echocardiographically guided group (Group E) and a non-guided group (Group N), the analysis focused on detailed patient data encompassing hospital stay, 30-day readmission and wound complications. Findings revealed that Group E experienced a significantly shorter average hospital stay of 3.5 days, compared with 6.5 days in Group N, along with a lower 30-day readmission rate (5% vs. 18% in Group N). Furthermore, Group E showed a considerable reduction in surgical site wound complications, such as infections and hematomas. The study concludes that echocardiographic guidance in LAA closure procedures markedly improves postoperative wound outcomes, underscoring its potential as a standard practice in cardiac surgeries for AF patients. This approach not only optimizes patient safety and postoperative recovery but also enhances healthcare resource utilization.
Participants in this group will receive flat doses of mitomycin C intra-operatively: 1) 30mg at minute 0 and 2) 10mg at minute 60. Mitomycin C will be delivered via HIPEC (hyperthermic intraperitoneal chemotherapy).
Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement, in a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate protein expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers, in most ALS patients with symptom onsets within two years, many of the ALS pathology biomarkers such as TOP 43, SOD1 and Tau were over expressed (Higher than normal range) at baseline. The patients treated with GM604 had these over-expressed biomarkers lowered to approach normal range, a sign of homeostasis. On the other hand, in an end stage ALS patient, the CSF SOD1 and CSF Tau were below normal range at baseline, treatment of GM604 up regulated them to approach normal range. This phenomenon that GM604 can modulate the same biomarker in both up and down direction is the hallmark of bringing homeostasis. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations. Comparing blood-based biomarkers between treatment and placebo groups, plasma Tau levels decreased 28% in the treated group at week 6 (p=0.04), plasma TDP-43 levels decreased 30% in the treated group at week 12. The slope in plasma TDP-43 through week 12 in GM604 treated patients (-3.513 pg/ml/wk) is lower than that in placebo treated patients (0,493 pg/ml/wk), with statistical significance, (p=0.008). SOD1 levels were also lowered in the treated group at week 2 while all three biomarker levels were increased in the placebo group (p=0.055>. The patients treated with GM604 also had more favorable clinical observation in Forced Vital Capacity (FVC) from screening to week 12 than the placebo group (p=0.0476), the decline in FVC was significantly reduced in the treated group. This correlation of disease progression with the modulation of the biomarkers suggest that GM604 can be used effectively in modulating ALS disease biomarkers, and consequently can be used for prognosis of ALS disease progression and therapeutic treatment to slow down ALS disease progression. The biomarker modulation can be a measure of drug efficacy.
The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
PURPOSE OF REVIEW: Existing definitions of clinically important weight loss in patients with cancer do not specifically address weight loss in patients who are obese at presentation. This review explores the clinical impact of weight loss and depletion of the skeletal muscle mass (i.e., criteria defining cancer cachexia), in patients with obesity.
RECENT FINDINGS: Overweight and obese BMI values are shown by many recent studies to pose a survival advantage in patients with cancers of advanced stage, when compared with BMI in normal and underweight ranges. The classification of cancer-associated weight loss has evolved, and current grading schemes evaluate the impact of weight across the range of BMI values. Weight loss is associated with mortality in patients with BMI more than 30 kg/m 2 , however this is to a much lesser degree than in patients with lower BMI values. Diagnostic imaging permits the precise assessment of skeletal muscle index (SMI) in patients with cancer, and it has been clearly shown that while usually quite muscular, obese patients can have profound muscle depletion (i.e., sarcopenia), independent of the presence of weight loss. Muscle depletion associates strongly with mortality in obese patients, as well as with complications of cancer surgery and systemic therapy.
SUMMARY: It would seem contradictory to diagnose concurrent obesity and cachexia, as these terms represent opposite ends of the weight spectrum. Weight loss can occur in anyone with cancer, however its priority for clinical management may be lesser in obese versus low body weight individuals. Sarcopenic obesity is strongly associated with a poor clinical outcome and deserves further research, diagnosis in clinical practice, and new strategies for mitigation.
PROBLEM TO BE SOLVED: To prepare the subject medicine containing as an active ingredient a specific extract obtained from a highly safe food, and capable of inhibiting the release of a phlogogenic substance such as histamine generated by an allergic reaction, etc. SOLUTION: The seeds of highly safe Avena fatua L. having been used as a food are extracted with water and/or a water-soluble organic solvent such as methanol, and the obtained extract is used. The extract is especially an ethyl acetate fraction obtained by extracting the Avena fatua L. with the water and/or the water-soluble organic solvent and subsequently fractionating the extract with water and ethyl acetate. The Avena fatua L. extract has an inhibiting action on the release of the histamine generated by the irritation of an antigen-antibody reaction calcium ionosphere, compound 48/80, etc., to basocytes and mastocytes. The inhibiting medicine is useful as a medicine for preventing various inflammatory symptoms such as bronchial asthma and atopic dermatitis caused by histamine. The daily dose of the inhibiting medicine is approximately 10-5000mg as the extract (dry weight).
Association analyses between longitudinal changes in diet quality scores (DQIs) and cardiometabolic risk remain scarce. Hence, we aimed to investigate how changes in two DQIs are associated with incident type 2 diabetes (T2D), myocardial infarction (MI) and stroke in the EPIC-Potsdam study. Changes in the Mediterranean Pyramid Score (MedPyr) and Healthy Diet Score (HDS) over 7 years from baseline (1994-1998) to follow-up 3 (2001-2005) were investigated in 23,548 middle-aged participants. Adjusted Cox Proportional Hazards Regression models were applied to investigate associations between changes in MedPyr and HDS and chronic disease incidence. More than 60% of the participants increased both DQIs more than 5%. Within a median follow-up time of 5 years 568 cases of T2D, 171 of MI, 189 of stroke were verified. An increased compared to stable MedPyr was associated with lower T2D risk (HR 0.74; 95% CI 0.59-0.92), while a decreased MedPyr was associated with higher stroke risk (HR 1.67; 95% CI 1.02-2.72). A decreased compared to stable HDS was associated with higher stroke risk (HR 1.80; 95% CI 1.02-3.20). The findings contribute further evidence on advantages of changing dietary intake towards a Mediterranean Diet. Although baseline HDS adherence was associated with T2D and stroke risk, longitudinal changes in HDS were only significantly associated with stroke risk.
This invention provides an antisense oligonucleotide or analog thereof comprising 10 or more contiguous bases or base analogs from the sequence of bases of sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG.  1 . This invention also provides the above-described antisense oligonucleotides, wherein the nucleotide sequence comprises nucleotide sequence A, A′, B, C, C′, D, E, E′, F, G, G′, H, H′, I, I′, J, K, K′, L, L′, M, or M′ of FIGS.  2 A and  2 B. This invention also provides the above-described antisense oligonucleotides, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle. This invention also provides the above-described antisense oligonucleotides, wherein the phosphate backbone comprises phosphorothioate bonds. In addition, this invention provides a method of treating cancer, comprising introducing into a tumor cell an effective amount of the the above-described antisense oligonucleotide, thereby reducing the levels of bcl-xL protein produced and treating cancer. This invention also provides the above-described methods, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent. This invention also provides the above-described pharmaceutical compositions, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle. This invention further provides the above-described pharmaceutical compositions, wherein the pharmaceutical composition comprises tetra meso-(4-methylpyridyl)porphine or tetra meso-(anilinium)porphine or a combination thereof.
Use of a swellable intermediate layer comprising a swellable material from the starch, starch derivatives e.g. pre-gelled starch, sodium-carboxyethyl starch, sodium-starchglycolate and cellulose, for releasing the solid medicament formulation for pre-oral application in a continuously extended manner. The formulation comprises a substrate containing active substance, the swellable intermediate layer and a retardant coating layer for adjusting the release profile of the active substance, where the retardant coating layer allows the complete release of the substance towards the end. Use of a swellable intermediate layer comprising a swellable material from the starch, starch derivatives like pre-gelled starch, sodium-carboxyethyl starch, sodium-starchglycolate, cellulose, cellulose ether such as hydroxypropylmethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, sodium-carboxymethylcellulose, carrageenan, alginate, pectin, xanthane and their derivatives, guar gum, tragant and/or polyvinylpyrrolidone, for releasing the solid medicament formulation for pre-oral application in an continuously extended manner. The formulation comprises a substrate containing active substance, the swellable intermediate layer and a retardant coating layer for adjusting the release profile of the active substance, where the retardant coating layer allows the complete release of the substance towards the end. Independent claims are also included for: (1) a solid medicament formulation for pre-oral application in a continuously extended manner and for adjusting release profile of the active substance, which permits an essentially complete release towards end in effective quantity; and (2) a delayed release of solid medicament formulation.
This is an open label, multiple cohorts, dose escalation Phase Ib study, in which up to 3 doses of VLX103 will be assessed for safety, pharmacodynamics and pharmacokinetics in well defined moderate ASH patients cohorts receiving increasing doses of VLX103. The overall study design is characteristic for early phase, first in patient clinical evaluation of safety and pharmacodynamics, especially when prudent dose escalation is recommended. A maximum of 18 moderate ASH patients will be enrolled and treated in at least 4 clinical sites throughout the US. The open label nature of the study design will allow to efficiently monitor the safety of VLX103 throughout the trial, and taking rapid decisions about dosing adjustments (dose reduction or discontinuation within each dosing cohort, for each patient).

After an adequate screening period (Day -7 to -1), all eligible patients of the first dosing cohort will receive the initial, low dose of VLX103 150 mg per day (QD) for 14 consecutive days. Subjects will be evaluated only for safety, pharmacodynamics and pharmacokinetics during this period. Pre-established safety criteria will be used to decide upon dose escalation, for each subject. If patients tolerate well VLX103 at 150 mg QD , a second cohort will then receive a 300 mg QD regimen for 14 days. At the end of this period, safety, pharmacodynamics and pharmacokinetics will be assessed as well. The next dose will be 450 mg QD for 14 days, with the same monitoring process. Long term safety will also be assessed, at all 3 doses, at Day 30 and 90 post treatment initiation.
The invention relates to a recipe and a method for treating incorporative small intestinal channel and stomach channel diseases by traditional Chinese medicine. The medicine recipe comprises 3g of fistular onion stalk, 3g of bamboo leaf, 3g of scutellaria baicalensis, 3g of folium isatidis, 3g of oldenlandia diffusa, 3g of bupleurum falcatum, 1g of rheum officinale, 3g of croton, 2g of silkworm excrement, 2g of loofah sponge, 2g of alpinia katsumadai, 2g of spora lygodii, 2g of bixie, 2g of long pepper, 3g of pericarpium arecae, 2g of gizzard pepsin, 2g of pseudo-ginseng, 2g of cowherb seed, 2g of rhizoma acori graminei 2g of Chinese date, 3g of radix glehniae and 3g of asparagus fern. Acupuncture points of da ying, shimonoseki, cheek crevice, qishe, t'ien jung, warehouse, quyuan, ju chung, tai yi, tiao kou, yanglao, houxi and neiting are selected. Auxiliary appliances comprise a foreign matter discharge barrel, a medicine guide-in barrel, an auxiliary barrel, an ozone generator, a foreign matter discharge ultrasonic generator and the like. Auxiliary articles comprise purified water, the fistular onion stalk and limonite. The recipe and the method can cure incorporative small intestinal channel and stomach channel diseases and can be used in clinical application.
BACKGROUND: Genome-wide association studies of COVID-19 severity have been carried out mostly on European or East Asian populations with small representation of other world regions. Here we explore the worldwide distribution and linkage disequilibrium (LD) patterns of genetic variants previously associated with COVID-19 severity.
METHODS: We followed up the results of a large Spanish genome-wide meta-analysis on 26 populations from the 1000 Genomes Project by calculating allele frequencies and LD scores of the nine most significant SNPs. We also used the entire set of summary statistics to compute polygenic risk scores (PRSs) and carried out comparisons at the population and continental level.
RESULTS: We observed the strongest differences among continental regions for the five top SNPs in chromosome 3. European, American, and South Asian populations showed similar LD patterns. Average PRSs in South Asian and American populations were consistently higher than those observed in Europeans. While PRS distributions were similar among South Asians, the American populations showed striking differences among them.
CONCLUSIONS: Considering the caveats of PRS transferability across ethnicities, our analysis showed that American populations present the highest genetic risk score, hence potentially higher propensity, for COVID-19 severity. Independent validation is warranted with additional summary statistics and phenotype data.
The present invention relates to a novel compound with utility as a drug with the effects of reducing hyperglycemia, hyperlipidemia, and oxidative stress. Said compound possesses a pharmacophore group that can interact with PPAR and could be a promising candidate for treating type 2 diabetes. Also, it aims to provide a compound with biological activity to treat or prevent diabetes and dyslipidemia as part of the pathologies of metabolic syndrome. The pharmacological results of the administration of IG in a model of type 2 diabetes demonstrate that it produces superior and similar effects to IOP. The test results suggest that 1G is an antioxidant molecule acting under a mechanism of action identical to IOP. Furthermore, a double TZD ring generates a structural advantage that triggers better glycemic-lowering activity.
The invention designs a series of active targeting nano carriers of polypeptide modified chitosan, and belongs to the technical field of medicines. Polypeptide as the target head of the nano carrier material is designed by novel medicine auxiliary design software MOE2011, and a series of polypeptides are obtained by investigation of docking energy and are synthesized by a solid-phase synthesis method. The main body material of the nano carrier is 6-O carboxylated chitosan. The preparation method comprises the following steps: by taking 1-ethyl-(3-dimethyl amino propyl) carbonyl diimine hydrochloride (EDC. Hcl) as a catalyst, successfully grafting the target head polypeptide to 6-O carboxylated chitosan; representing through infrared spectroscopy and nuclear magnetic resonance; and successfully preparing nanoparticles by an ionic gelation method by the material, wherein the safety and targeting are verified through a series of in vitro cell experiments. The result shows that the material as the safe and effective nano targeting carrier has an extremely good prospect.
A method and system for applying colored dental adhesive and a high-resolution decal to the surface of a person's tooth. The colored dental adhesive is formed by combining dental adhesive with a food grade colorant. The high-resolution decal is formed by printing a design on a paper substrate. Before application of the colored dental adhesive, the tooth is cleaned and etched with a phosphoric acid compound. The colored dental adhesive is applied to the surface of a tooth. The decal is then placed on colored dental adhesive, and the colored dental adhesive is cured. Additional layers of dental adhesive may be applied on top of the decal.
The American approach to predicting sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy diverges from the European method in that it relies on major risk factors independently justifying the implantation of an implantable cardioverter-defibrillator for primary prevention, whereas the European approach uses a mathematical equation to estimate a 5-year risk percentage. The aim of this review is to outline the differences between the American and European guidelines and to show how they have arisen. Furthermore, it will provide insight into the future of SCD risk prediction in patients with hypertrophic cardiomyopathy. The American SCD risk prediction method has high sensitivity but limited specificity, whereas the European method has the opposite. These differences in sensitivity and specificity likely contribute to the fact that primary prevention implantable cardioverter-defibrillator utilization is twofold higher in the United States. It is highly likely that new insights and new imaging modalities will enhance prediction models in the near future. Genotyping could potentially assume a significant role. Left ventricular global longitudinal strain was recently shown to be an independent predictor of SCD. Furthermore, after late gadolinium enhancement, additional cardiac magnetic resonance techniques such as T1 mapping and diffusion tensor imaging are showing encouraging outcomes in predicting SCD. Ultimately, it is conceivable that integrating diverse morphological and genetic characteristics through deep learning will yield novel insights and enhance SCD prediction methods.
BACKGROUND: Human papillomavirus (HPV) infection is an important factor leading to cervical cell abnormalities. 90% of cervical cancers are closely associated with persistent infection of high-risk HPV, with the highest correlation with HPV16 and 18. Currently available vaccines and antivirals have limited effectiveness and coverage. Guanylate binding protein 1 (GBP1) was induced by interferon gamma and involved in many important cellular processes such as clearance of various microbial pathogens. However, whether GBP1 can inhibit human papillomavirus infection is unclear.
RESULTS: In this study, we found that GBP1 can effectively degrade HPV18 E6, possibly through its GTPase activity or other pathways, and E6 protein degrades GBP1 through the ubiquitin-proteasome pathway to achieve immune escape.
CONCLUSION: Therefore, GBP1 is an effector of IFN-γ anti-HPV activity. Our findings provided new insights into the treatment of HPV 18 infections.
Tranexamic acid tablets are an antifibrinolytic drug administered orally. The chemical name is trans-4-aminomethyl-cyclohexanecarboxylic acid. The structural formula is:

Tranexamic acid is a white crystalline powder. It is freely soluble in water and in glacial acetic acid and is very slightly soluble in ethanol and practically insoluble in ether. The molecular formula is C8H15N02 and the molecular weight is 157.2.

Tranexamic acid tablets are provided as white to off-white, oval-shaped, unscored, film coated tablets, debossed with “WPI 3720” on one side of the tablet. The active ingredient in each tablet is 650 mg tranexamic acid. The inactive ingredients contained in each tablet are: colloidal silicon dioxide, copovidone, crospovidone, dimethylaminoethyl methacrylate - butyl methacrylate - methyl methacrylate copolymer, glyceryl behenate, lactose monohydrate, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and triethyl citrate.
Variations in oxygen level affect the phenotype of cells and extracellular vesicles (EVs). Depending on the metabolic oxygen demand of cells, hypoxic cell culture can produce conditions more like those found in vivo, and with appropriate oxygen levels, mimic hypoxic tumours. However, most previous experiments studying both EVs and the effects of hypoxia on cells use periods of 72 h or less of hypoxia. We hypothesised that this was insufficient time for adaptation to hypoxic conditions both for EVs and cells which may skew the results of such studies. In this study, the effects of acute (72 h) and chronic hypoxia (> 2 weeks) on the phenotype of HepG2 and PC3 cells and their EVs were examined. Cells could be cultured normally under chronic hypoxic conditions and cryopreserved and recovered. The effects of hypoxia on EV phenotype are slow to establish and dependent on cell line. In PC3 cells, the greatest change in phenotype and increase in EV production occurred only with chronic hypoxic culture. In HepG2 cells, the number of EVs produced was insensitive to hypoxic culture and the greatest changes in protein expression were observed after acute hypoxic culture. Nonetheless, biphasic changes in EV phenotype were detected in both cell types in response to either acute or chronic hypoxia. These results indicate that for cells which do not induce consumptive oxygen depletion, prolonged hypoxic culture is required for complete adaptation.